PROFESSIONAL EDITION

The largest community of pharma leaders

Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery

SAN DIEGO–(BUSINESS WIRE)– #breastcancer–Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles